Screening for Congenital Adrenal Hyperplasia: Adjustment of 17-Hydroxyprogesterone Cut-Off Values to Both Age and Birth Weight Markedly Improves the Predictive Value
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Newborn screening procedures for congenital adrenal hyperplasia (CAH) are still suboptimal because of low specificity, particularly in premature infants. This study evaluated a multitiered strategy for reporting abnormal 17-hydroxyprogesterone screening values that simultaneously takes into account not only birth weight but also age at sampling. A cautious three-tiered cut-off scheme was used during the initial 24 months of CAH screening in Bavaria. Data were then reanalyzed using five birth weight classes to reflect more precisely the markedly higher values in low-birth-weight newborns. Because 17-hydroxyprogesterone values apparently decline with increasing age, these classes were then further subdivided into a total of 21 groups according to the age at sampling. Based on this reanalysis, we defined new multitiered cut-off levels and used them for the next 18 months. A total of 538466 newborns were screened from January 1999 to June 2002; 51 CAH cases were detected. Application of the new threshold values resulted in a 35% reduction of the total recall rate (from 1.13% to 0.74%) and an increase in the positive predictive value from 0.84% to 1.29% without reducing diagnostic sensitivity. This improvement of CAH screening can be achieved by simply using request forms that ask for both age and birth weight at the time of sampling.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Radioimmunoassay (RIA) was the first method developed (250), but automated time-resolved dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA) has almost completely supplanted other immunoassays (251).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [251]
In the citing paper
“There are no universally accepted standards for stratifying infants, but most laboratories use a series of birth weight-adjusted cut-offs (65-67).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [66]
Citations
Cites
Speiser, P. W., Dupont, J., Zhu, D., Serrat, J., Buegeleisen, M., Tusie-Luna, M. T., Lesser, M., New, M. I., & White, P. C. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115897 · Cited by 572
Krone, N., Braun, A., Roscher, A. A., Knorr, D., & Schwarz, H. P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.3.6441 · Cited by 397
Self-citationPang, S., Wallace, M. A., Hofman, L., Thuline, H. C., Dorche, C., Lyon, I. C. T., Dobbins, R. H., Kling, S., Fujieda, K., & Suwa, S. (1988) · Journal of Urology · doi:10.1016/s0022-5347(17)42164-1 · Cited by 392
Wedell, A. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.78.5.1145 · Cited by 370
Therrell, B. L., Berenbaum, S. A., Manter-Kapanke, V., Simmank, J., Korman, K., Prentice, L., Gonzalez, J., & Gunn, S. (1998) · Pediatrics · doi:10.1542/peds.101.4.583 · Cited by 344
Molecular and clinical advances in congenital adrenal hyperplasia
Miller, W. L., & Levine, L. S. (1987) · The Journal of Pediatrics · doi:10.1016/s0022-3476(87)80334-7 · Cited by 178
(1991) · Europe PMC (PubMed Central) · Cited by 164
Wong, T., Shackleton, C. H., Covey, T. R., & Ellis, G. (1992) · Clinical Chemistry · doi:10.1093/clinchem/38.9.1830 · Cited by 159
Allen, D. B., Hoffman, G. L., Fitzpatrick, P., Laessig, R., Maby, S., & Slyper, A. (1997) · The Journal of Pediatrics · doi:10.1016/s0022-3476(97)70321-4 · Cited by 153
Caulfield, M. P., Lynn, T., Gottschalk, M. E., Jones, K. L., Taylor, N. F., Malunowicz, E. M., Shackleton, C. H. L., Reitz, R. E., & Fisher, D. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.8.8712 · Cited by 120
Cited by
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
PW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
Chien, Y.-H., Chiang, S.-C., Zhang, X. K., Keutzer, J., Lee, N.-C., Huang, A.-C., Chen, C.-A., Wu, M.-H., Huang, P.-H., Tsai, F.-J., et al. (2008) · Pediatrics · doi:10.1542/peds.2007-2222 · Cited by 242
Neonatal screening for congenital adrenal hyperplasia
White, P. C. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.148 · Cited by 240
Forest, M. G. (2004) · Human Reproduction Update · doi:10.1093/humupd/dmh047 · Cited by 200
“Recent experience in which the adjustment of 17-OHP threshold values to both age and birthweight (Olgemoller et al., 2003), and/or improved specificity of the method used (mass spectrometry) (Lacey et al.”
MethodAdrenal Steroidogenesis and Congenital Adrenal Hyperplasia
Turcu, A. F., & Auchus, R. J. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.02.002 · Cited by 177
Combined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis
Anakk, S., Watanabe, M., Ochsner, S. A., McKenna, N. J., Finegold, M. J., & Moore, D. D. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42846 · Cited by 129
“can be reached in congenital adrenal hyperplasia (46).”
BackgroundCongenital adrenal hyperplasia and P450 oxidoreductase deficiency
Krone, N., Dhir, V., Ivison, H. E., & Arlt, W. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02740.x · Cited by 131
Steroid measurement with LC–MS/MS. Application examples in pediatrics
Rauh, M. (2009) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2009.12.007 · Cited by 113
Steroid 21-hydroxylase deficiency in congenital adrenal hyperplasia
Parsa, A. A., & New, M. I. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.06.015 · Cited by 104
Schwarz, E., Liu, A., Randall, H., Haslip, C., Keune, F., Murray, M., Longo, N., & Pasquali, M. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e3181aa3777 · Cited by 97
“The 17-OHP levels, measured by EIA, decrease with increasing birth weight and increasing age at collection (11).”
BackgroundProfiles of 21-Carbon Steroids in 21-Hydroxylase Deficiency
Turcu, A. F., Rege, J., Chomic, R., Liu, J., Nishimoto, H. K., Else, T., Moraitis, A. G., Palapattu, G. S., Rainey, W. E., & Auchus, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1023 · Cited by 77
Kaur, G., Srivastav, J., Jain, S., Chawla, D., Chavan, B. S., Atwal, R., Randhawa, G., Kaur, A., & Prasad, R. (2010) · The Indian Journal of Pediatrics · doi:10.1007/s12098-010-0150-x · Cited by 76
“Variations due to these factors were incorporated into defining values and this markedly reduced the rate of false-positives for 17OHP [9].”
BackgroundInfluentialNewborn Screening for Congenital Adrenal Hyperplasia: Review of Factors Affecting Screening Accuracy
Held, P. K., Bird, I. M., & Heather, N. L. (2020) · International Journal of Neonatal Screening · doi:10.3390/ijns6030067 · Cited by 79
“All newborn screening programs should consider use of higher 17OHP cutoff values in premature babies, adjusting for gestational age and/or birthweight, to minimize false positives [21,24].”
BackgroundThe next 150 years of congenital adrenal hyperplasia
Turcu, A. F., & Auchus, R. J. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.05.013 · Cited by 70
Kyriakopoulou, L., Yazdanpanah, M., Colantonio, D. A., Chan, M. K., Daly, C. H., & Adeli, K. (2013) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2013.01.002 · Cited by 68
“Partitioning of reference intervals can significantly increase the sensitivity and specificity of steroid hormone assays, thus improving the diagnosis and monitoring of various endocrine disorders in children [19].”
BackgroundNewborn screening for congenital adrenal hyperplasia in New Zealand, 1994-2013
Heather, N. L., Seneviratne, S. N., Webster, D., Derraik, J. G. B., Jefferies, C., Carll, J., Jiang, Y., Cutfield, W. S., & Hofman, P. L. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3168 · Cited by 65
“Our calculations were made based on data from 2011 to 2013, after the introduction of 17-OHP cutoff levels stratified by birth weight and are comparable with other programs that have incorporated multitiered thresholdsbasedonbirthweightorgestational age (23, 24).”
MethodNewborn screening for congenital adrenal hyperplasia has reduced sensitivity in girls
Varness, T. S., Allen, D. B., & Hoffman, G. L. (2005) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2005.04.035 · Cited by 61
The Effects of Gestational Age and Birth Weight on False-Positive Newborn-Screening Rates
Slaughter, J. L., Meinzen‐Derr, J. K., Rose, S. R., Leslie, N. D., Chandrasekar, R., Linard, S. M., & Akinbi, H. T. (2010) · PEDIATRICS · doi:10.1542/peds.2010-0943 · Cited by 61
Fingerhut, R. (2009) · Steroids · doi:10.1016/j.steroids.2009.02.008 · Cited by 59
Self-citationKösel, S., Burggraf, S., Fingerhut, R., Dörr, H. G., Roscher, A. A., & Olgemöller, B. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.042416 · Cited by 52
Self-citationHayashi, G. Y., Carvalho, D. F., de Miranda, M. C., Faure, C., Vallejos, C., Brito, V. N., Rodrigues, A. D. S., Madureira, G., Mendonca, B. B., & Bachega, T. A. S. S. (2017) · Clinical Endocrinology · doi:10.1111/cen.13292 · Cited by 52
Congenital adrenal hyperplasia: an update in children
Trapp, C. M., Speiser, P. W., & Oberfield, S. E. (2011) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e328346938c · Cited by 50
Expanded newborn screening in Greece: 30 months of experience
Loukas, Y. L., Soumelas, G., Dotsikas, Y., Georgiou, V., Molou, E., Thodi, G., Boutsini, M., Biti, S., & Papadopoulos, K. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9181-8 · Cited by 46
“used the cutoffs set by Olgemoller et al. (2003) .”
MethodHuynh, T., McGown, I. N., Cowley, D. M., Nyunt, O., Leong, G. M., Harris, M. A., & Cotterill, A. M. (2009) · PubMed · Cited by 60
Cavarzere, P., Samara-Boustani, D., Flechtner, I., Dechaux, M., Elie, C., Tardy, V., Morel, Y., & Polak, M. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0145 · Cited by 41
“5 [8-186] pg/mL and 46 [20-112] pg/mL for simple false positives and hyper-17OHPemia infants, respectively.”
BackgroundMethodNewborn screening for congenital adrenal hyperplasia in New York State
Pearce, M., DeMartino, L., McMahon, R., Hamel, R., Maloney, B., Stansfield, D.-M., McGrath, E. C., Occhionero, A., Gearhart, A., Caggana, M., et al. (2016) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2016.02.005 · Cited by 44
“In Bavaria, adjustments are made to cut-offs depending on age at sampling, in addition to birth weight [29].”
BackgroundPode‐Shakked, N., Blau, A., Pode‐Shakked, B., Tiosano, D., Weintrob, N., Eyal, O., Zung, A., Levy‐Khademi, F., Tenenbaum‐Rakover, Y., Zangen, D., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02468 · Cited by 40
Gleeson, H. K., Wiley, V., Wilcken, B., Elliott, E., Cowell, C., Thonsett, M., Byrne, G., & Ambler, G. (2008) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2008.01383.x · Cited by 39
Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision)
Ishii, T., Anzo, M., Adachi, M., Onigata, K., Kusuda, S., Nagasaki, K., Harada, S., Horikawa, R., Minagawa, M., Minamitani, K., et al. (2015) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.24.77 · Cited by 40
Navarro-Zambrana, A. N., & Sheets, L. (2022) · Hormone Research in Paediatrics · doi:10.1159/000526401 · Cited by 42
Kopacek, C., de Castro, S. M., Prado, M. J., da Silva, C. M. D., Beltrão, L. A., & Spritzer, P. M. (2017) · BMC Pediatrics · doi:10.1186/s12887-016-0772-x · Cited by 41
“Adjustment of diagnostic levels of 17-OHP according to birth weight tiers [7, 9, 10, 19] has been proposed as a”
BackgroundZetterström, R. H., Karlsson, L., Falhammar, H., Lajić, S., & Nordenström, A. (2020) · International Journal of Neonatal Screening · doi:10.3390/ijns6030071 · Cited by 38
Turcu, A. F., El-Maouche, D., Zhao, L., Nanba, A. T., Gaynor, A., Veeraraghavan, P., Auchus, R. J., & Merke, D. P. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0129 · Cited by 33
Zhao, L.-Q., Su, H., & Tian, H. (2008) · World Journal of Pediatrics · doi:10.1007/s12519-008-0016-8 · Cited by 32
Strnadová, K. A., Votava, F., Lebl, J., Mühl, A., Item, C., Bodamer, O. A., Torresani, T., Bouška, I., Waldhauser, F., & Sperl, W. (2006) · European Journal of Pediatrics · doi:10.1007/s00431-006-0154-8 · Cited by 30
“Positive samples from premature babies were re-evaluated with birthweight and age-adjusted cut-off levels [7].”
Dhillon, K., Ho, T., Rich, P., Xu, D., Lorey, F., She, J., & Bhandal, A. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.07.009 · Cited by 33
Newborn screening for inborn errors of metabolism and endocrinopathies: an update
Fingerhut, R., & Olgemöller, B. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2505-y · Cited by 31
Self-citationCongenital Adrenal Hyperplasia: Issues in Diagnosis and Treatment in Children
Sharma, R., & Seth, A. (2013) · The Indian Journal of Pediatrics · doi:10.1007/s12098-013-1280-8 · Cited by 30
“Preterm babies have higher serum 17OHP levels and different cut-off values are used for CAH screening [12].”
MethodBialk, E. R., Lasarev, M. R., & Held, P. K. (2019) · International Journal of Neonatal Screening · doi:10.3390/ijns5030033 · Cited by 25
Hird, B. E., Tetlow, L., Tobi, S., Patel, L., & Clayton, P. E. (2014) · Archives of Disease in Childhood · doi:10.1136/archdischild-2013-304473 · Cited by 25
Newborn Screening and Diagnosis of Infants with Congenital Adrenal Hyperplasia
Vats, P., Dabas, A., Jain, V., Seth, A., Yadav, S., Kabra, M., Gupta, N., Singh, P., Sharma, R., Kumar, R., et al. (2020) · Indian Pediatrics · doi:10.1007/s13312-020-1703-3 · Cited by 25
A three-year follow-up of congenital adrenal hyperplasia newborn screening
Pezzuti, I. L., Barra, C. B., Mantovani, R. M., Januário, J. N., & Silva, I. N. (2014) · Jornal de Pediatria · doi:10.1016/j.jped.2013.09.007 · Cited by 26
21-Deoxycortisol is a Key Screening Marker for 21-Hydroxylase Deficiency
Held, P. K., Bialk, E. R., Lasarev, M. R., & Allen, D. B. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.10.063 · Cited by 23
Cavarzere, P., Camilot, M., Teofoli, F., & Tatò, L. (2005) · Hormone Research in Paediatrics · doi:10.1159/000085021 · Cited by 29
Update: Newborn Screening for Endocrinopathies
Pass, K. A., & Neto, E. C. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2009.08.005 · Cited by 22
Newborn Screening for Congenital Adrenal Hyperplasia in India: What Do We Need to Watch Out for?
Kumar, R. K., Das, H., & Kini, P. (2015) · The Journal of Obstetrics and Gynecology of India · doi:10.1007/s13224-015-0712-y · Cited by 22
“The prevalence rates of CAH in the USA and Europe are approximately 1:15,000–16,000, and slightly lower in Japan (1:19,000) [17, 18].”
BackgroundJiang, X., Tang, F., Feng, Y., Li, B., Jia, X., Tang, C., Liu, S., & Huang, Y. (2019) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2019-0140 · Cited by 21
Newborn screening for congenital adrenal hyperplasia in Cuba: Six years of experience
Reyes, E. C. G., Carvajal, F., Frómeta, A., Arteaga, A. L., Martínez, E. M. C., Espinosa, T., Coto, R., Pérez, P. L., Tejeda, Y., del Río, L., et al. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.02.020 · Cited by 21
Németh, S., Riedl, S., Kriegshäuser, G., Baumgartner-Parzer, S., Concolino, P., Neocleous, V., Phylactou, L. A., Borucka-Mankiewicz, M., Onay, H., Tukun, A., et al. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.09.013 · Cited by 20
Pilot proficiency testing study for second tier congenital adrenal hyperplasia newborn screening
De Jesús, V. R., Simms, D. A., Schiffer, J., Kennedy, M., Mei, J. V., & Hannon, W. H. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.06.029 · Cited by 20
Maffazioli, G. D. N., Bachega, T. A. S. S., Hayashida, S. A. Y., Gomes, L. G., Valassi, H. P. L., Marcondes, J. A. M., Mendonca, B. B., Baracat, E. C., & Maciel, G. A. R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa369 · Cited by 21
CAH Newborn Screening in India: Challenges and Opportunities
Dabas, A., Bothra, M., & Kapoor, S. (2020) · International Journal of Neonatal Screening · doi:10.3390/ijns6030070 · Cited by 20
“There may be high false positive rates with the first-tier immunoassay due to cross-reactivity and physiological changes in the concentration of 17OHP during the first few days of life, especially in preterm neonates [12].”
Backgroundde Miranda, M. C., Haddad, L. B. D. P., Madureira, G., Mendonca, B. B., & Bachega, T. A. S. S. (2019) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz013 · Cited by 22
“However, the high frequency of false-positive results remains a major issue [2, 11], especially in preterm newborns [12].”
BackgroundApplication of principal component analysis to newborn screening for congenital adrenal hyperplasia
Lasarev, M. R., Bialk, E. R., Allen, D. B., & Held, P. K. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa371 · Cited by 19
Triagem neonatal para hiperplasia adrenal congênita
Barra, C. B., Silva, I. N., Pezzuti, I. L., & Januário, J. N. (2012) · Revista da Associação Médica Brasileira · doi:10.1590/s0104-42302012000400017 · Cited by 19
Yang, Q., Xu, L., Tang, L., Yang, J., Wu, B., Chen, N., Jiang, J., & Yu, R. (2018) · Talanta · doi:10.1016/j.talanta.2018.04.081 · Cited by 18
Kopacek, C., Prado, M. J., da Silva, C. M. D., de Castro, S. M., Beltrão, L. A., Vargas, P. R., Grandi, T., Rossetti, M. L. R., & Spritzer, P. M. (2019) · Jornal de Pediatria · doi:10.1016/j.jped.2018.03.003 · Cited by 17
Development of CYP21A2 Genotyping Assay for the Diagnosis of Congenital Adrenal Hyperplasia
Prado, M. J., de Castro, S. M., Kopacek, C., de Mello, M. P., Rispoli, T., Grandi, T., da Silva, C. M. D., & Rossetti, M. L. R. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-017-0296-6 · Cited by 18
Quality performance of newborn screening systems: Strategies for improvement
WEBSTER, D. R. (2007) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-007-0639-2 · Cited by 17
“17-OHP) where the normal range is highly dependent on the maturity of the baby, the use of cut-offs adjusted for gestational age or birth weight (Borrajo et al 2006; Olgemoller et al 2003; Sherwin et al 2006 )h as improved specificity.”
BackgroundFariha, R., Jabrah, M., Hill, C., Spooner, A., Deshpande, P. S., & Tripathi, A. (2022) · SLAS TECHNOLOGY · doi:10.1016/j.slast.2022.01.006 · Cited by 16
Votava, F., Novotná, D., Kračmar, P., Vinohradská, H., Stahlova-Hrabincova, E., Vrzalová, Z., Neumann, D., Malíková, J., Lebl, J., & Matern, D. (2012) · European Journal of Pediatrics · doi:10.1007/s00431-011-1656-6 · Cited by 16
“Newborn screening for CAH by application of an immunoassay for the measurement of 17OHP is associated with a high FPR and low PPV, particularly in neonates with low birth weight [2, 6, 7, 17].”
Methodde Hora, M. R., Heather, N. L., WEBSTER, D. R., Albert, B. B., & Hofman, P. L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1226284 · Cited by 15
Chennuri, V. S., Mithbawkar, S. M., Mokal, R. A., & Desai, M. P. (2012) · The Indian Journal of Pediatrics · doi:10.1007/s12098-012-0856-z · Cited by 16
Reyes, E. C. G., González, N. M., Pérez, P. L., Frómeta, A., Rodríguez, O. Z., Vallejera, D. H., Martínez, L., & Martínez, E. M. C. (2008) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.04.004 · Cited by 14
3?-hydroxysteroid dehydrogenase type II deficiency on newborn screening test
de Araújo, V. G. B., Oliveira, R., Gameleira, K. P. D., Cruz, C. B., & Lofrano‐Porto, A. (2014) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/0004-2730000003098 · Cited by 15
Fernández, B. H., Fernández, M. E., Íñiguez, E. D., Zubicaray, B. E., Martín, M. B. R., Arnao, M. D. R., & Sánchez, A. R. (2011) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2011.007 · Cited by 13
Maloney, B., Park, S., Sowizral, M., Brackett, I., Moslehi, R., Chung, W. K., Gruber, D., Brower, A., Lloyd-Puryear, M. A., Caggana, M., et al. (2023) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2023.110614 · Cited by 13
Neonatal screening for congenital adrenal hyperplasia
Barra, C. B., Silva, I. N., Pezzuti, I. L., & Januário, J. N. (2012) · Revista da Associação Médica Brasileira (English Edition) · doi:10.1016/s2255-4823(12)70229-1 · Cited by 12
Newborn screening for congenital adrenal hyperplasia: beyond 17-hydroxyprogesterone concentrations
Witchel, S. F. (2018) · Jornal de Pediatria · doi:10.1016/j.jped.2018.06.003 · Cited by 13
Newborn Screening Healthcare Information System Based on Service-Oriented Architecture
Hsieh, S.-H., Hsieh, S.-L., Chien, Y., Weng, Y.-C., Hsu, K.-P., Chen, C., Tu, C.-M., Wang, Z., & Lai, F. (2009) · Journal of Medical Systems · doi:10.1007/s10916-009-9265-x · Cited by 10
“NSHIS provides a wide range of facilities for presentation and interrogation for MS/MS raw data [34, 35 ].”
BackgroundDisorders of Sexual Differentiation
Shnorhavorian, M., & Fechner, P. Y. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-40139-5.00097-8 · Cited by 10
A Newborn Screening System Based on Service-Oriented Architecture Embedded Support Vector Machine
Hsu, K.-P., Hsieh, S.-H., Hsieh, S.-L., Cheng, P., Weng, Y.-C., Wu, J.-H., & Lai, F. (2009) · Journal of Medical Systems · doi:10.1007/s10916-009-9305-6 · Cited by 9
Ambiguous Genitalia in the Newborn
Lin‐Su, K., & New, M. I. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0134-0.10092-7 · Cited by 9
Yoon, Y. A., Woo, S., Kim, M. S., Kim, B., & Choi, Y. (2023) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2022-8399 · Cited by 7
“Some studies adjusted the cutoff value to BW, GA, and GA with sampling time [5, 6, 16, 19].”
BackgroundDörr, H. G., Odenwald, B., & Nennstiel, U. (2015) · International Journal of Neonatal Screening · doi:10.3390/ijns1010036 · Cited by 8
Pearce, M., Dauerer, E., DiRienzo, A. G., Caggana, M., & Tavakoli, N. P. (2016) · European Journal of Pediatrics · doi:10.1007/s00431-016-2814-7 · Cited by 6
Cavarzere, P., Mauro, M., Vincenzi, M., Lauriola, S., Teofoli, F., Gaudino, R., Ramaroli, D. A., Micciolo, R., Camilot, M., & Antoniazzi, F. (2018) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-018-0444-6 · Cited by 6
Neonatal screening for congenital adrenal hyperplasia
Barra, C. B., Silva, I. N., Pezzuti, I. L., & Januário, J. N. (2012) · Revista da Associação Médica Brasileira · doi:10.1016/s0104-4230(12)70229-4 · Cited by 6
Blocs enzymatiques précoces de la surrénale
Samara‐Boustani, D., Bachelot, A., Pinto, G., Thibaud, E., Polak, M., & Touraine, P. A. (2008) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(08)40173-7 · Cited by 6
21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia
Shaw, A. (2010) · Neonatal Network The Journal of Neonatal Nursing · doi:10.1891/0730-0832.29.3.191 · Cited by 5
Síndrome de Klinefelter de presentación atípica
Marcos, N. S., Turon-Viñas, A., & Ibáñez, L. (2012) · Anales de Pediatría · doi:10.1016/j.anpedi.2012.10.020 · Cited by 5
Newborn Screening for Phenylketonuria: Machine Learning vs Clinicians
Chen, W., Chen, H.-P., Tseng, Y., Hsu, K.-P., Hsieh, S.-L., Chien, Y., Hwu, W., & Lai, F. (2012) · IEEE/ACM International Conference on Advances in Social Networks Analysis and Mining (ASONAM) · doi:10.1109/asonam.2012.145 · Cited by 4
Somboonnithiphol, K., Panamonta, O., Kiatchoosakun, P., Jirapradittha, J., Panamonta, M., Lumbiganon, P., & Somsapt, P. (2011) · Asian Biomedicine · doi:10.5372/1905-7415.0506.112 · Cited by 4
“Therefore, the normative reference levels based on birth weight or gestational age were used to minimize false positive rates and improve the efficacy of newborn screening for CAH, particularly in low birth weight newborns [8-10].”
MethodSzteroid-21-hidroxiláz-deficientia, a congenitalis adrenalis hyperplasia leggyakoribb oka
Doleschall, M., Török, D., Mészáros, K. V., Luczay, A., Halász, Z., Németh, K., Szücs, N., Kiss, R., Tõke, J., Sólyom, J., et al. (2018) · Orvosi Hetilap · doi:10.1556/650.2018.30986 · Cited by 5
“[15] Olgemöller B, Roscher AA, Liebl B, et al.”
BackgroundMultiple 17-OHP Cutoff Co-Variates Fail to Improve 21-Hydroxylase Deficiency Screening Accuracy
Matharu, P. K., Held, P. K., & Allen, D. B. (2022) · International Journal of Neonatal Screening · doi:10.3390/ijns8040057 · Cited by 5
“However, the decision was made to use BW because estimation of gestational age is less accurate given variable dating methods; several other studies have also proven that birth weight is a reliable co-variate to use for the adjustment of 17OHP levels, with a significant improvement in false positive rates for screenin…”
MethodHyperplasie congénitale des surrénales: les formes précoces
Samara‐Boustani, D., Bachelot, A., Pinto, G., Thibaud, E., Touraine, P. A., & Polak, M. (2009) · EMC - Pédiatrie - Maladies infectieuses · doi:10.1016/s1637-5017(09)72438-x · Cited by 4
Kum, C. D., Lee, M. J., Park, M. S., Sohn, Y. B., Noh, O. K., & Lee, J. H. (2019) · Neonatal Medicine · doi:10.5385/nm.2019.26.1.41 · Cited by 3
Jomaa, D., Hawken, S., Lawrence, S. L., Chakraborty, P. K., & Henderson, M. (2021) · Journal of Laboratory and Precision Medicine · doi:10.21037/jlpm-21-18 · Cited by 3
“In addition to GA-based screening, efforts to reduce the false positive rate have included adjusting 17-OHP thresholds to the age of blood sample collection and collecting a second blood sample from screen positive newborns and repeating screening (13,17).”
BackgroundAdrenocortical Function in Preterm Infants
Chung, H. R. (2015) · Neonatal Medicine · doi:10.5385/nm.2015.22.3.124 · Cited by 3
Interpretation of screening for congenital adrenal hyperplasia in preterm infants
Chung, H. R., Shin, C. H., Yang, S. W., Yun, K. A., Lee, Y. A., Park, S., Choi, C. W., Kim, B. I., Choi, J.-H., & Song, J. (2008) · Korean Journal of Pediatrics · doi:10.3345/kjp.2008.51.6.616 · Cited by 3
A Newborn Screening System Based on Service-Oriented Architecture Embedded Support Vector Machine
Hsieh, S.-H., Hsieh, S.-L., Chien, Y., Wang, Z., Weng, Y.-C., & Lai, F. (2008) · IEEE International Symposium on Service-Oriented System Engineering (SOSE) · doi:10.1109/sose.2008.58 · Cited by 3
“Moreover, the manipulating strategies of multi-tiered cut-off schemes [6–8] without conjunction with clinical observations, additional sampling simultaneously, lower sensitivities, specificities or predictive values for metabolic disorder diseases can occur.”
BackgroundGenotypic spectrum of 21-hydroxylase deficiency in an endogamous population
Mahmoud, R. A. A., Amr, N. H., Toaima, N. N., Kamal, T. M., & Elsedfy, H. H. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01648-8 · Cited by 4
Lawrence, S. E., Marcadier, J., Auger, S., Bariciak, E., Chakraborty, P. K., Chambers, A., Eagle, S., Kowalskil, M., Marr, A., McIntosh, N., et al. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf157 · Cited by 2
Neonatal screening for Duchenne muscular dystrophy in eastern China: a closed prospective study
Qian, G., Yang, R., Huang, X., Wu, D., Fang, K., & Zhao, Z. (2026) · Translational Pediatrics · doi:10.21037/tp-2025-aw-808 · Cited by 2
“…CAH, are closely related to gestational age and birth weight, so different cut-off values are usually set for different gestational ages and birth weights (25,26); however, in CK-MM screening, these factors do not seem sufficient to affect the segmented settings required to establish cutoff values.”
Kopacek, C., Prado, M. J., da Silva, C. M. D., de Castro, S. M., Beltrão, L. A., Vargas, P. R., Grandi, T., Rossetti, M. L. R., & Spritzer, P. M. (2019) · Jornal de Pediatria (Versão em Português) · doi:10.1016/j.jpedp.2018.05.003 · Cited by 10
El cribado neonatal de la hiperplasia suprarrenal congénita: una revision sistemática
Liste, T. R., & Caeiro, Á. L. G. (2007) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(07)71435-3 · Cited by 5
Endocrine components of newborn screening
Russell, M. (2020) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2020.100772 · Cited by 2
Metadata
- Authors
- Olgemöller, B., Roscher, A. A., Liebl, B., & Fingerhut, R.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Fingerhut, Ralph
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-12
- Volume
- 88
- Issue
- 12
- Pages
- 5790-5794
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2034018965
- Cited by
- 124
- References
- 25
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 4 · 2022: 4 · 2021: 5 · 2020: 10 · 2019: 9 · 2018: 9 · 2017: 2 · 2016: 7 · 2015: 7 · 2014: 5 · 2013: 5 · 2012: 9
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- congenital adrenal hyperplasia, newborn screening, 17-hydroxyprogesterone, cut-off values, birth weight, positive predictive value, recall rate, preterm infants
- MeSH terms
- Adrenal Hyperplasia, Congenital, Aging, Birth Weight, False Negative Reactions, Germany, Humans, Infant, Infant, Newborn, Predictive Value of Tests, Sensitivity and Specificity, Incidence, Neonatal Screening, 17-alpha-Hydroxyprogesterone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.